Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$1.46 - $5.91 $3,974 - $16,087
-2,722 Reduced 15.11%
15,298 $81,000
Q4 2023

Feb 14, 2024

SELL
$0.96 - $1.55 $266 - $430
-278 Reduced 1.52%
18,020 $26,000
Q3 2022

Nov 08, 2022

SELL
$1.54 - $3.21 $23,870 - $49,755
-15,500 Reduced 45.86%
18,298 $28,000
Q1 2022

May 16, 2022

BUY
$2.11 - $7.25 $71,313 - $245,035
33,798 New
33,798 $84,000

Others Institutions Holding CRDF

About Cardiff Oncology, Inc.


  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $109M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Atom Investors LP Portfolio

Follow Atom Investors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Atom Investors LP, based on Form 13F filings with the SEC.

News

Stay updated on Atom Investors LP with notifications on news.